Form 4: Kevin Rakin Acquires Stock Options in Elutia Inc.

Director Kevin Rakin acquired 47,753 stock options in Elutia Inc. on June 6, 2024, under the company's Non-Employee Director Compensation Program.

Summary

• Kevin Rakin, a director and 10% owner of Elutia Inc., acquired 47,753 stock options on June 6, 2024.
• The options were granted under the Issuer's Non-Employee Director Compensation Program.
• The exercise price of the options is $3.40.
• The options vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to continued service on the board.
• The expiration date for the options is June 5, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally to positively as it aligns interests. There are no indications of distress or unusual activity.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the options suggests an expectation of continued service by the director.

Industry Context

Granting stock options to directors is a common practice to align their interests with those of shareholders and incentivize long-term value creation. This is a standard component of director compensation packages in many publicly traded companies.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a common practice across various industries to align their interests with shareholders.
• The vesting schedule, typically tied to continued service, is also a standard feature in such grants.
• The specific number of options and exercise price would be benchmarked against peer companies of similar size and industry within the biotechnology sector.

Stakeholder Impact

• Shareholders may view the option grant positively as it aligns the director's interests with long-term value creation.
• The director is incentivized to contribute to the company's success to realize the value of the options.

Key Dates